Study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502440-12-00

Acronym

PRADR/ET22-313

Enrollment

Registered

2023-08-11

Start date

2023-11-16

Completion date

Unknown

Last updated

2024-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic clear cell renal cancer with progressive disease after 2 lines of therapy in the advanced/metastatic setting including at least 1 line of anti-VEGFR and 1 line of immunotherapy.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France

Outcome results